Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks

Dirk Rades; Primoz Strojan; Daniel Seidl; Stefan Janssen; Amira Bajrovic; Nadja Kazic; Samer G Hakim; Barbara Wollenberg; Steven E Schild

doi:10.1016/j.jcms.2016.06.033

Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks

Standard

Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. / Rades, Dirk; Strojan, Primoz; Seidl, Daniel; Janssen, Stefan; Bajrovic, Amira; Kazic, Nadja; Hakim, Samer G; Wollenberg, Barbara; Schild, Steven E.

In: J CRANIO MAXILL SURG, Vol. 44, No. 9, 09.2016, p. 1436-40.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rades, D, Strojan, P, Seidl, D, Janssen, S, Bajrovic, A, Kazic, N, Hakim, SG, Wollenberg, B & Schild, SE 2016, 'Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks', J CRANIO MAXILL SURG, vol. 44, no. 9, pp. 1436-40. https://doi.org/10.1016/j.jcms.2016.06.033

APA

Rades, D., Strojan, P., Seidl, D., Janssen, S., Bajrovic, A., Kazic, N., Hakim, S. G., Wollenberg, B., & Schild, S. E. (2016). Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. J CRANIO MAXILL SURG, 44(9), 1436-40. https://doi.org/10.1016/j.jcms.2016.06.033

Vancouver

Rades D, Strojan P, Seidl D, Janssen S, Bajrovic A, Kazic N et al. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. J CRANIO MAXILL SURG. 2016 Sep;44(9):1436-40. https://doi.org/10.1016/j.jcms.2016.06.033

Bibtex

@article{f4c502ba6bd54c8ebaab67f61eabf985,

title = "Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks",

abstract = "Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m(2) cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m(2) cisplatin plus 600/1000 mg/m(2) 5-FU on days 1-5 and days 29-33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m(2) of cisplatin require close monitoring of their renal function.",

keywords = "Journal Article",

author = "Dirk Rades and Primoz Strojan and Daniel Seidl and Stefan Janssen and Amira Bajrovic and Nadja Kazic and Hakim, {Samer G} and Barbara Wollenberg and Schild, {Steven E}",

year = "2016",

month = sep,

doi = "10.1016/j.jcms.2016.06.033",

language = "English",

volume = "44",

pages = "1436--40",

journal = "J CRANIO MAXILL SURG",

issn = "1010-5182",

publisher = "Elsevier",

number = "9",

}

RIS

TY - JOUR

T1 - Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks

AU - Rades, Dirk

AU - Strojan, Primoz

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Kazic, Nadja

AU - Hakim, Samer G

AU - Wollenberg, Barbara

AU - Schild, Steven E

PY - 2016/9

Y1 - 2016/9

N2 - Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m(2) cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m(2) cisplatin plus 600/1000 mg/m(2) 5-FU on days 1-5 and days 29-33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m(2) of cisplatin require close monitoring of their renal function.

AB - Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy. The optimal regimen is still unclear when considering both efficacy and feasibility. This study compared two regimens for locoregional control (LRC), overall survival (OS), and adverse events. Data of 329 patients with LASCCHN receiving definitive or postoperative radiochemotherapy were retrospectively analyzed. A total of 131 patients received 100 mg/m(2) cisplatin on days 1, 22, and 43 (group A), and 198 patients received 20 mg/m(2) cisplatin plus 600/1000 mg/m(2) 5-FU on days 1-5 and days 29-33 (group B). Radiochemotherapy regimens plus nine factors were compared for LRC and OS, and radiochemotherapy regimens additionally for adverse events. On univariate analysis, chemotherapy type was not associated with LRC (p = 0.36). On multivariate analysis, performance score (p = 0.039), N-category (p = 0.007), histologic grade (p = 0.007), upfront surgery (p = 0.030), and pre-radiochemotherapy hemoglobin levels (p < 0.001) were associated with LRC. On univariate analysis, chemotherapy type had no impact on OS (p = 0.64). On multivariate analysis, performance score (p < 0.001), T-category (p = 0.025), N-category (p < 0.001), histologic grade, and hemoglobin levels (p < 0.001) were associated with OS. Renal failure occurred significantly more often in group A (p = 0.008). Otherwise, adverse events were not significantly different. Thus, both radiochemotherapy regimens appeared similarly effective for LASCCHN. Patients receiving 100 mg/m(2) of cisplatin require close monitoring of their renal function.

KW - Journal Article

U2 - 10.1016/j.jcms.2016.06.033

DO - 10.1016/j.jcms.2016.06.033

M3 - SCORING: Journal article

C2 - 27499514

VL - 44

SP - 1436

EP - 1440

JO - J CRANIO MAXILL SURG

JF - J CRANIO MAXILL SURG

SN - 1010-5182

IS - 9

ER -